<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: <z:mp ids='MP_0001845'>Inflammatory responses</z:mp> have been implicated in the elaboration of several forms of central <z:mp ids='MP_0008912'>nervous</z:mp> system injury, including <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> after <z:hpo ids='HP_0002138'>subarachnoid hemorrhage</z:hpo> (SAH) </plain></SENT>
<SENT sid="1" pm="."><plain>A critical event participating in such responses is the recruitment of circulating leukocytes into the inflammatory site </plain></SENT>
<SENT sid="2" pm="."><plain>Two of the key <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecules responsible for the attachment of leukocytes to endothelial cells are intercellular <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule-1 (ICAM-1) and the common beta chain of the integrin superfamily (CD18) </plain></SENT>
<SENT sid="3" pm="."><plain>This study examined the effects of monoclonal antibodies on ICAM-1 and the effects of CD18 on <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> after SAH </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: A rabbit model of SAH was utilized to test the influence of intracisternally administered antibodies to ICAM-1 and CD18 on <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Antibodies were administered alone or in combination, and the cross-sectional area of basilar arteries was assessed histologically on day 2 post-SAH </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Treatment with antibodies to ICAM-1 or CD18 inhibited vasospasm by 22% and 27%, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>When administered together, the attenuation of vasospasm increased to 56% </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> of these effects achieved statistical significance </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: These findings provide the first evidence that the severity of <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> can be attenuated using monoclonal antibodies against ICAM-1 and CD18 </plain></SENT>
<SENT sid="10" pm="."><plain>The results reinforce the concept that cell-mediated <z:mp ids='MP_0001845'>inflammation</z:mp> plays an important role in <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> after SAH and suggest that therapeutic targeting of cellular <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecules can be of benefit in treating <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> </plain></SENT>
</text></document>